Cleveland Diagnostics' prostate cancer blood test gets breakthrough status

By staff writers

October 16, 2019 -- Cleveland Diagnostics' IsoPSA blood test for prostate cancer has been designated by the U.S. Food and Drug Administration as a breakthrough device, which allows greater collaboration with officials and typically a faster regulatory review.

The product is among a range of noninvasive assays developed to improve blood testing for levels of prostate-specific antigen (PSA), which may rise for reasons other than prostate cancer and lead to unnecessary follow-up procedures. PSA testing also presents a risk of detecting indolent cancers that would not affect a patient's life span.

According to the company, the IsoPSA test is better than traditional PSA testing when it comes to identifying riskier types of prostate tumors, and it could reduce the number of unnecessary biopsies by at least 45%.

The test has been evaluated in two multicenter studies led by the Cleveland Clinic. In one study of 271 men scheduled for prostate biopsies, the area under the curve for distinguishing high-grade versus low-grade cancer was 0.784, concluded a group led by Dr. Mark Stovsky, chief medical officer at Cleveland Diagnostics and a urologist at the Cleveland Clinic (Stovsky et al, Journal of Urology, June 2019, Vol. 201:6, pp. 1115-1120).

BRCA status leads the way in screening men for prostate cancer
Blood testing for levels of prostate-specific antigen gets a bad rap, but a targeted approach is gaining support. A large study published online September...
Invitae offers 4 more no-charge genetic tests
Invitae has opened enrollment to U.S. consumers for free genetic testing and counseling services for four more conditions through its underwritten testing...
Urologic pathologist hops aboard OncoCell MDx
Urologic pathology specialist Dr. Kirk Wojno is now the chief medical officer at OncoCell MDx, a privately held company that is developing noninvasive,...
Syntaphilin shines as biomarker for aggressive prostate cancer
The mitochondrial protein syntaphilin could be the key in identifying prostate cancer patients who have more aggressive disease and a poorer prognosis,...

Copyright © 2019

Last Updated np 10/16/2019 1:23:03 PM